ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

BRH Braveheart Investment Group Plc

5.25
0.00 (0.00%)
26 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Braveheart Investment Group Plc LSE:BRH London Ordinary Share GB00B13XV322 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.25 5.00 5.50 5.25 5.25 5.25 58,501 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Management Services 51k 1.59M 0.0249 2.11 3.35M
Braveheart Investment Group Plc is listed in the Management Services sector of the London Stock Exchange with ticker BRH. The last closing price for Braveheart Investment was 5.25p. Over the last year, Braveheart Investment shares have traded in a share price range of 4.00p to 15.00p.

Braveheart Investment currently has 63,723,489 shares in issue. The market capitalisation of Braveheart Investment is £3.35 million. Braveheart Investment has a price to earnings ratio (PE ratio) of 2.11.

Braveheart Investment Share Discussion Threads

Showing 3751 to 3771 of 3800 messages
Chat Pages: 152  151  150  149  148  147  146  145  144  143  142  141  Older
DateSubjectAuthorDiscuss
15/5/2024
17:03
Classic Trevor.
kemche
15/5/2024
16:35
Another TB story.
clocktower
15/5/2024
13:05
not a good rns ...why not just wait and include in results.

This could drop significantly today. Those selling today take a look at KRS and KDNC you can make your money up as they have double bagger potential

citys2874
15/5/2024
13:05
horrible news but when others are selling , mr trevor is in the background ready to pounce , director buy on way
casino444
15/5/2024
12:38
Cardiac arrest - Cremation soon?
pugugly
09/5/2024
12:35
In the tip?
kemche
04/3/2024
08:19
We have been done over with the Sale!
urchin1
08/2/2024
10:27
SYME IS NOW READY TO FLY
vaston
08/2/2024
10:23
Ready to pop?
targatarga
29/12/2023
11:35
Given that the Paraytec gizmo was designed to detect more than sepsis it could be worth anything to the right company. Imo 30p+ a share would be fair value.
chavitravi2
29/12/2023
09:50
Is that 3p a share then? Didnt we invest £2.5m in this?
chavitravi2
22/12/2023
18:23
£2.1m cash / 64m shs = 0.032p
euclid5
22/12/2023
09:31
If sale of this goes through that's 2.1 million cash after costs Market cap of Braveheart is 5 million.Paraytec will hopefully be a lot more.
targatarga
22/12/2023
08:57
Surprised these haven't risen more on this!
targatarga
20/12/2023
02:48
There is increasing interest in the the development of diagnostics for people with blood-borne bacterial infections. If left untreated, patients will develop sepsis - an acute and life-limiting physiological response which arises from inflammatory signals generated by the immune system. These signals emerge as neutrophils - specialised white blood cells - try to contain the infection, which they do by committing suicide and in so doing extruding their DNA and cellular content to generate a physical net or trap that catches and kills infecting bacteria.



For clinicians, people with blood with blood-borne infections present two challenges:-

(i) what is the nature of the infection (bacteraemia) and how to bring it under control, and

(ii) whether an infection will precipitate sepsis, requiring acute treatment to ensure the patient can avoid septic shock and survive long enough to allow for (i) to happen.



When clinicians suspect bacteraemia, the major challenge is concerned with diagnosis and identification of the infectious species, which determines the nature of antibiotic treatment required. At present, this takes up to 48h and involves lengthy culture of blood samples to enable specific identification of the bacteria present.



The recent reports of tests for sepsis ( specfically designed to detect the traps set by dying neutrophils, enabling clinicians to treat the life-threatening aspects of sepsis which include a sudden drop in blood pressure, blood-clotting, blood vessel damage and tissue/organ failure. These tests are complementary to the approach adopted by Paraytec Ltd , and allow clinicians to address (ii) but do nothing to address (i).



The Paraytec test is designed to address the issue outlined in (i), using molecular diagnostics and highly sensitive optical imaging to detect the presence of bacteria in samples obtained from blood without prior culture, and to distinguish Gram + from Gram - bacteria. Knowing the Gram status of organisms allows clinicians to make key decisions about antibiotic selection, as well as to suggest the source of infection enabling additional interventional measures.

ydderf
14/12/2023
08:26
Interesting trading statement ref decision to sell paraytec; should see some buying ahead of further news; time to load up
mdw1
19/9/2023
14:27
What a bargain these are just now with all the things we have coming good. when we get half decent news this will double easy. There are at least 3 projects ready to pop.
chavitravi2
01/8/2023
10:19
Paraytec will be bought out very soon, out of the blue RNS the proceeds paid out in a dividend imo, you got to be in it to win it
c31161
28/7/2023
16:14
A few 5ok trades in the pipe apparently
targatarga
28/7/2023
15:04
Marvellous...
killman2
28/7/2023
14:42
That’s a great Rns re Paraytec, impressive results
mdw1
Chat Pages: 152  151  150  149  148  147  146  145  144  143  142  141  Older